Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
2012
|
| Schlagworte: | |
| Online-Zugang: | Volltext Inhaltsverzeichnis |
| Beschreibung: | Zsfassung in dt. und engl. Sprache. - Online erschienen: 2014 |
| Beschreibung: | 174 S. Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV041617015 | ||
| 003 | DE-604 | ||
| 005 | 20140224 | ||
| 007 | t | ||
| 008 | 140131s2012 ad|| m||| 00||| eng d | ||
| 035 | |a (OCoLC)869895918 | ||
| 035 | |a (DE-599)BVBBV041617015 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-473 |a DE-703 |a DE-1051 |a DE-824 |a DE-29 |a DE-12 |a DE-91 |a DE-19 |a DE-1049 |a DE-92 |a DE-739 |a DE-898 |a DE-355 |a DE-706 |a DE-20 |a DE-1102 | ||
| 084 | |a XH 3204 |0 (DE-625)152888:12910 |2 rvk | ||
| 100 | 1 | |a Ehrig, Klaas |d 1983- |e Verfasser |0 (DE-588)1047004798 |4 aut | |
| 245 | 1 | 0 | |a Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy |c von Klaas Ehrig |
| 246 | 1 | 3 | |a Effekte von Stammzell-Transkriptionsfaktor exprimierenden Vaccinia Viren in onkolytischer Virotherapie |
| 264 | 1 | |c 2012 | |
| 300 | |a 174 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Zsfassung in dt. und engl. Sprache. - Online erschienen: 2014 | ||
| 502 | |a Würzburg, Univ., Diss., 2012 | ||
| 650 | 0 | 7 | |a Vaccinia-Virus |0 (DE-588)4187306-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Transkriptionsfaktor |0 (DE-588)4303350-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Lungenkrebs |0 (DE-588)4036668-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Darmkrebs |0 (DE-588)4011068-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Darmkrebs |0 (DE-588)4011068-0 |D s |
| 689 | 0 | 1 | |a Lungenkrebs |0 (DE-588)4036668-6 |D s |
| 689 | 0 | 2 | |a Transkriptionsfaktor |0 (DE-588)4303350-7 |D s |
| 689 | 0 | 3 | |a Vaccinia-Virus |0 (DE-588)4187306-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |o urn:nbn:de:bvb:20-opus-85139 |
| 856 | 4 | 1 | |u https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-85139 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027058112&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-027058112 | ||
Datensatz im Suchindex
| _version_ | 1804151825327194112 |
|---|---|
| adam_text | CONTENTS
ZUSAMMENFASSUNG 1
SUMMARY 4
1 INTRODUCTION 7
1.1 CANCER OCCURRENCE IN HUMANS 7
1.2 CAUSES OF CANCER 8
1.3 CLASSIFICATION AND MORPHOLOGY OF CANCER 10
1.3.1 LUNG CANCER 10
1.3.2 COLORECTAL CANCER 12
1.4 STEM CELLS 17
1.4.1 STEM CELL TRANSCRIPTION FACTOR OCTAMER-BINDING TRANSCRIPTION
FACTOR (OCT4) 20
1.4.2 STEM CELL TRANSCRIPTION FACTOR NANOG 22
1.4.3 STEM CELL TRANSCRIPTION FACTOR KRUEPPEL-LIKE FACTOR 4 (KLF4) 23
1.5 CANCER STEM CELLS 26
1.6 THE RELATION BETWEEN STEM CELLS AND CANCER STEM CELLS 27
1.7 NOVEL APPROACHES IN CANCER THERAPY 29
1.7.1 ONCOLYTIC VIRUSES IN CANCER THERAPY AND DIAGNOSIS 30
1.8 VACCINIA VIRUS 31
1.8.1 MORPHOLOGY 32
1.8.2 VACCINIA VIRUS REPLICATION CYCLE 32
1.8.3 TARGETED AND ARMED ONCOLYTIC POXVIRUSES 33
1.8.4 RECOMBINANT VACCINIA VIRUS CONSTRUCTS USED IN THIS WORK 35
1.9 AIMS OF THIS WORK 35
2 MATERIAL 38
2.1 CHEMICALS AND ENZYMES 38
2.2 BUFFERS AND SOLUTIONS 41
2.3 BACTERIAL STRAINS 45
HTTP://D-NB.INFO/1048540928
TABLE OF CONTENTS
2.4 CELL LINES AND CELL CULTURE MEDIA 45
2.4.1 CELL LINES 45
2.4.2 CELL CULTURE MEDIA 46
2.5 KITS ! 48
2.6 ANTIBODIES 49
2.7 SYNTHETIC OLIGONUCLEOTIDES 49
2.8 RECOMBINANT VACCINIA VIRUS CONSTRUCTS 50
2.9 LABORATORY ANIMALS 53
2.10 LABORATORY EQUIPMENT AND OTHER MATERIALS 53
2.11 MICROSCOPES 55
3 METHODS 56
3.1 GENERATION OF RECOMBINANT VACCINIA VIRUS 56
3.1.1 CLONING OF PLASMIDS FOR HOMOLOGOUS RECOMBINATION WITH VIRAL DNA 56
3.1.2 CO-TRANSFECTION OF PLASMID DNA WITH PARENTAL VIRUS GLV-1 H68 56
3.1.3 PLAQUE SELECTION 56
3.1.4 SCREENING FOR MARKER GENE EXPRESSION 57
3.1.5 SCREENING FOR GPT. 57
3.1.6 DNA ISOLATION FOR SEQUENCING 58
3.1.7 AMPLIFICATION AND PURIFICATION OF RECOMBINANT VIRUSES 58
3.1.8 DETERMINATION OF VIRAL TITERS BY STANDARD PLAQUE ASSAY 58
3.2 VIROLOGICAL METHODS 59
3.2.1 INFECTION OF CELL CULTURES 59
3.2.2 VIRAL PROLIFERATION ASSAY 59
3.2.3 STANDARD PLAQUE ASSAY 59
3.3 CELL BIOLOGICAL METHODS 59
3.3.1 CULTURING OF ADHERENT MAMMALIAN CELLS 59
3.3.2 CELL VIABILITY ASSAY 60
3.4 DETECTION OF GENE EXPRESSION OF RECOMBINANT VACCINIA VIRUS 60
3.4.1 ANALYSIS OF GENE EXPRESSION BY REVERSE TRANSCRIPTASE (RT-) PCR 60
TABLE OF CONTENTS
3.4.1.1 ISOLATION OF RNA FROM ADHERENT MAMMALIAN CELLS 60
3.4.1.2 SYNTHESIS OF COMPLEMENTARY DNA (CDNA) 61
3.4.1.3 POLYMERASE CHAIN REACTION (PCR) 61
3.4.1.4 AGAROSE GEL ELECTROPHORESIS 61
3.4.1.5 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QPCR) 61
3.4.2 QUANTIFICATION OF GFP EXPRESSION BY FACS ANALYSIS 62
3.4.3 FLUORESCENCE IMAGING AND IMMUNOCYTOCHEMISTRY 62
3.5 PROTEIN ANALYTICAL METHODS 62
3.5.1 PREPARATION OF SOLUBLE PROTEINS FROM MAMMALIAN CELLS 62
3.5.2 ULTRAFILTRATION OF CELL SUPERNATANTS 63
3.5.3 PROTEIN QUANTIFICATION 63
3.5.4 SDS-PAGE 63
3.5.5 PROTEIN TRANSFER BY WESTERN BLOT 64
3.5.6 IMMUNODETECTION 64
3.5.7 ELISA 65
3.6 MOUSE EXPERIMENTS 65
3.6.1 SUBCUTANEOUS XENOGRAFTS 65
3.6.2 ANESTHESIA 65
3.6.3 VACCINIA VIRAL TITERS IN TUMOR TISSUES AND BODY ORGANS 66
3.6.4 PREPARATION OF TUMOR LYSATES FOR MOUSE IMMUNE-RELATED PROTEIN
PROFILING 66
3.6.5 DETECTION OF VIRUS-ENCODED MARKER GENE RUC-GFP EXPRESSION 66
3.6.6 HISTOLOGICAL ANALYSIS OF TUMORS 66
4 RESULTS 68
4.1 CHARACTERIZATION OF STEM CELL TRANSCRIPTION FACTOR-ENCODING VACCINIA
VIRUSES GLV-
1H205 (NANOG) AND GLV-1H208 (OCT4) 68
4.1.1 VIRUS MEDIATED STEM CELL TRANSCRIPTION FACTOR EXPRESSION 68
4.1.1.1 ANALYSIS OF VIRAL REPLICATION IN THE CANCER CELL LINES A549 AND
PC-3 68
4.1.1.2 ANALYSIS OF VACCINIA VIRUS EXPRESSED MRNA TRANSCRIPTS OF MARKER
GENES AND
STEM CELL TRANSCRIPTION FACTORS NANOG AND OCT4 IN INFECTED MAMMALIAN
CELLS 70
4.1.1.3 ANALYSIS OF RECOMBINANT PROTEIN EXPRESSION IN INFECTED MAMMALIAN
CELLS 71
TABLE OF CONTENTS
4.1.1.3.1 ANALYSIS OF BETA-GALACTOSIDASE EXPRESSION IN INFECTED
MAMMALIAN CELLS 71
4.1.1.3.2 ANALYSIS OF RUC-GFPXAND STEM CELL TRANSCRIPTION FACTOR
EXPRESSION IN INFECTED
MAMMALIAN CELLS BY IMMUNOCYTOCHEMISTRY 72
4.1.1.3.3 ANALYSIS OF NANOG EXPRESSION IN INFECTED MAMMALIAN CELLS BY
ELISA
QUANTIFICATION 74
4.1.1.3.4 ANALYSIS OF OCT4 EXPRESSION IN INFECTED MAMMALIAN CELLS BY
WESTERN BLOT 75
4.1.1.4 ANALYSIS OF CELL VIABILITY OF MAMMALIAN CELL CULTURES INFECTED
WITH GLV-1 H205
AND GLV-1
H208 77
4.1.1.5 INFLUENCE OF NANOG EXPRESSION ON CELL CYCLE PROGRESSION IN
MAMMALIAN CELL
CULTURE 78
4.1.1.6 INFLUENCE OF NANOG AND OCT4 EXPRESSION ON EXPRESSION OF GENES
INVOLVED IN
EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) AFTER INFECTION OF A549 IN
CULTURE 80
4.1.2 EFFECTS OF A SINGLE DOSE OF GLV-1
H205 OR GLV-1 H208 IN SUBCUTANEOUS A549
XENOGRAFTS 82
4.1.2.1 CONFIRMATION OF VIRAL TUMOR INFILTRATION, INFECTION AND
REPLICATION BY GFP
FLUORESCENCE AND RENILLA LUCIFERASE LOW LIGHT IMAGING 84
4.1.2.2 PFU DETERMINATION IN VACCINIA VIRUS-INJECTED A549 TUMOR-BEARING
MICE AT
VARIOUS TIME POINTS 86
4.1.2.3 HISTOCHEMICAL ANALYSIS OF VACCINIA VIRUS COLONIZATION IN A549
MOUSE XENOGRAFTS
88
4.1.2.4 IMMUNE-RELATED ANTIGEN PROFILING OF A549 TUMOR-BEARING MICE
AFTER
ADMINISTRATION OF A SINGLE DOSE OF REPLICATION-COMPETENT VACCINIA VIRUS
STRAINS 89
4.1.3 CHARACTERIZATION OF A NANOGANLS MUTANT VIRUS 90
4.1.3.1 ANALYSIS OF VIRAL REPLICATION RATE OF GLV-1
H321 IN THE CANCER CELL LINE A549.... 91
4.1.3.2 ANALYSIS OF RECOMBINANT PROTEIN EXPRESSION IN MAMMALIAN CELLS
INFECTED WITH
GLV-1
H321 92
4.1.3.2.1 ANALYSIS OF BETA-GALACTOSIDASE EXPRESSION IN INFECTED
MAMMALIAN CELLS 92
4.1.3.2.2 ANALYSIS OF RUC-GFP AND NANOG EXPRESSION IN INFECTED MAMMALIAN
CELLS BY
IMMUNOCYTOCHEMISTRY 92
4.1.3.2.3 ANALYSIS OF NANOG EXPRESSION IN INFECTED MAMMALIAN CELLS BY
WESTERN BLOT.. 94
4.1.3.3 ANALYSIS OF CELL VIABILITY OF MAMMALIAN CELLS INFECTED WITH
GLV-1 H321 95
TABLE OF CONTENTS
4.1.3.4 EFFECTS OF A SINGLE DOSE OF GLV-1 H205 OR GLV-1 H321 IN
SUBCUTANEOUS A549
A
XENOGRAFTS 96
4.1.3.5 PFU DETERMINATION IN A549 TUMOR-BEARING MICE INJECTED WITH GLV-1
H68, GLV-
1H205, AND GLV-1 H321 AT VARIOUS TIME POINTS 97
4.1.3.6 EFFECTS OF A SINGLE DOSE OF GLV-1 H205 OR GLV-1 H321 IN
SUBCUTANEOUS DU-145
XENOGRAFTS 98
4.2 ONCOLYTIC VIROTHERAPY AS A TREATMENT OF COLORECTAL CANCER 99
4.2.1 EFFICACY OF GLV-1 H68 IN COLORECTAL CANCER THERAPY 99
4.2.1.1 REPLICATION OF GLV-1 H68 IN DIFFERENT HUMAN COLORECTAL CANCER
LINES IN CULTURE 99
4.2.1.2 CYTOTOXICITY OF GLV-1 H68 IN DIFFERENT COLORECTAL CANCER LINES
IN CULTURE 100
4.2.1.3 ANALYSIS OF VIRAL REPLICATION AND CYTOTOXICITY ON INFECTED HOST
CELLS USING VIRUS-
MEDIATED MARKER GENE EXPRESSION 101
4.2.1.4 EFFECTS OF A SINGLE DOSE OF GLV-1 H68 IN SUBCUTANEOUS CRC
XENOGRAFTS 104
4.2.1.5 ANALYSIS OF VIRAL TUMOR INFILTRATION, INFECTION AND REPLICATION
BY FLUORESCENCE
DETECTION OF VIRAL MARKER GENE (RUC-GFP) EXPRESSION 107
4.2.1.6 PFU DETERMINATION IN GLV-1 H68-INJECTED HCT-116 TUMOR-BEARING
MICE AT
VARIOUS TIME POINTS 108
4.2.1.7 HISTOCHEMICAL ANALYSIS OF GLV-1 H68 INJECTIONS IN HCT-116 MOUSE
XENOGRAFTS
109
4.2.1.8 IMMUNE-RELATED ANTIGEN PROFILING OF HCT-116 TUMOR-BEARING MICE
AFTER
ADMINISTRATION OF A SINGLE DOSE OF GLV-1 H68 110
4.3 IMPROVEMENT OF ONCOLYTIC VIROTHERAPY WITH A NEW
REPLICATION-COMPETENT VACCINIA
VIRUS STRAIN EXPRESSING TRANSCRIPTION FACTOR KLF4 111
4.3.1 A POTENTIAL APPLICATION OF TRANSCRIPTION FACTOR KLF4 IN COLORECTAL
CANCER 111
4.3.1.1 ANALYSIS OF VIRAL REPLICATION IN THE CRC LINES HCT-116 AND HT-29
112
4.3.1.2 ANALYSIS OF RECOMBINANT PROTEIN EXPRESSION IN INFECTED CRC CELLS
114
4.3.1.2.1 ANALYSIS OF BETA-GALACTOSIDASE EXPRESSION IN INFECTED CRC
CELLS 114
4.3.1.2.2 ANALYSIS OF RUC-GFP AND KLF4 EXPRESSION IN INFECTED CRC CELLS
BY
IMMUNOCYTOCHEMISTRY 115
4.3.1.2.3 ANALYSIS OF KLF4 EXPRESSION IN INFECTED HT-29 CELLS BY WESTERN
BLOT 117
TABLE OF CONTENTS
4.3.1.3 CELL VIABILITY OF HT-29 CELLS INFECTED WITH KLF4-ENCODING
VACCINIA VIRUSE STRAINS
GLV-1
H290-292 118
4.3.1.4 EFFECTS OF VIRUS-MEDIATED KLF4 EXPRESSION ON MRNA LEVELS OF
CELLULAR BETA-
CATENIN 120
4.3.1.5 EFFECTS OF VIRUS-MEDIATED KLF4 EXPRESSION ON CELLULAR PROTEIN
LEVELS OF BETA-
CATENIN 121
4.3.1.6 CONSTRUCTION AND CHARACTERIZATION OF THE KLF4-TAT FUSION
PROTEIN-EXPRESSING
VACCINIA VIRUS STRAIN GLV-1 H391 122
4.3.1.6.1 VIRAL REPLICATION OF GLV-1H391 IN COLORECTAL CANCER LINE HT-29
122
4.3.1.7 MARKER GENE EXPRESSION IN COLORECTAL CANCER LINE HT-29 INFECTED
WITH GLV-
1H391 123
4.3.1.7.1 ANALYSIS OF BETA-GALACTOSIDASE EXPRESSION IN INFECTED HT-29
CELLS 123
4.3.1.7.2 ANALYSIS OF RUC-GFP AND KLF4 EXPRESSION IN INFECTED A549 CELLS
BY
IMMUNOCYTOCHEMISTRY 124
4.3.1.7.3 ANALYSIS OF KLF4 EXPRESSION IN GLV-1
H391
-INFECTED HT-29 CELLS BY WESTERN BLOT
125
4.3.1.8 CELL VIABILITY OF HT-29 CELLS INFECTED WITH VACCINIA VIRUSE
STRAIN GLV-1H391.. 126
4.3.1.9 FUNCTIONAL ANALYSIS OF VIRUS-MEDIATED KLF4-TAT EXPRESSION 128
4.3.1.9.1 EFFECTS OF KLF4-TAT EXPRESSION ON CELLULAR BETA-CATENIN LEVELS
IN GLV-1 H391
INFECTED HT-29 CELLS 128
4.3.1.9.2 EFFECTS OF KTF4-TAT ON CELL PROLIFERATION 129
4.3.1.10 EFFECTS OF A SINGLE DOSE OF GLV-1 H205 OR GLV-1 H321 IN
SUBCUTANEOUS A549
XENOGRAFTS 130
4.3.1.11 PFU DETERMINATION IN HT-29 TUMOR-BEARING MICE INJECTED WITH
GLV-1 H68, GLV-
1H291, AND GLV-1 H391 AT 21 DAYS POST INJECTION 132
4.3.1.12 ANALYSIS OF VIRAL TUMOR INFILTRATION, INFECTION AND REPLICATION
BY IMAGING OF VIRAL
MARKER GENE (RUC-GFP) EXPRESSION 133
4.3.1.13 HISTOCHEMICAL ANALYSIS OF VIRAL TUMOR INFILTRATION AND GENE
EXPRESSION 134
5 DISCUSSION 136
5.1 TWO NEW STEM CELL TRANSCRIPTION FACTOR-ENCODING RECOMBINANT VACCINIA
VIRUS STRAINS
SHOW ONCOLYTIC POTENTIAL IN A549 NON-SMALL CELL LUNG CARCINOMA 137
5.2 THERAPEUTIC EFFICACY OF GLV-1
H205 AND GLV-1 H208 IN MOUSE XENOGRAFTS 139
TABLE OF CONTENTS
5.3 IS THE OBSERVED ENHANCED THERAPEUTIC EFFICACY OF GLV-1
H205 PAYLOAD- OR PROMOTER-
MEDIATED? 141
5.4 GLV-1 H68 AS A POTENTIAL THERAPEUTIC AGENT IN TREATMENT OF
COLORECTAL CANCER 143
5.5 IMPROVING THERAPEUTIC OUTCOME OF ONCOLYTIC VIROTHERAPY OF COLORECTAL
CANCER BY
SPECIFICALLY ARMED VACCINIA VIRUS STRAINS 145
5.6 CONCLUSION 148
6 REFERENCES 150
7 APPENDIX 168
7.1 ABBREVIATIONS 168
7.2 ACKNOWLEDGEMENTS 171
7.3 EIDESTATTLICHE ERKLARUNG 172
8 LEBENSLAUF 173
9 PUBLIKATIONEN 174
9.1 IM RAHMEN DIESER ARBEIT ENTSTANDENE PUBLIKATIONEN 174
|
| any_adam_object | 1 |
| author | Ehrig, Klaas 1983- |
| author_GND | (DE-588)1047004798 |
| author_facet | Ehrig, Klaas 1983- |
| author_role | aut |
| author_sort | Ehrig, Klaas 1983- |
| author_variant | k e ke |
| building | Verbundindex |
| bvnumber | BV041617015 |
| classification_rvk | XH 3204 |
| collection | ebook |
| ctrlnum | (OCoLC)869895918 (DE-599)BVBBV041617015 |
| discipline | Medizin |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02158nam a2200457 c 4500</leader><controlfield tag="001">BV041617015</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140224 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">140131s2012 ad|| m||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)869895918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV041617015</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1102</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3204</subfield><subfield code="0">(DE-625)152888:12910</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ehrig, Klaas</subfield><subfield code="d">1983-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1047004798</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy</subfield><subfield code="c">von Klaas Ehrig</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Effekte von Stammzell-Transkriptionsfaktor exprimierenden Vaccinia Viren in onkolytischer Virotherapie</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">174 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Zsfassung in dt. und engl. Sprache. - Online erschienen: 2014</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="a">Würzburg, Univ., Diss., 2012</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Vaccinia-Virus</subfield><subfield code="0">(DE-588)4187306-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Transkriptionsfaktor</subfield><subfield code="0">(DE-588)4303350-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Lungenkrebs</subfield><subfield code="0">(DE-588)4036668-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Darmkrebs</subfield><subfield code="0">(DE-588)4011068-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Darmkrebs</subfield><subfield code="0">(DE-588)4011068-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Lungenkrebs</subfield><subfield code="0">(DE-588)4036668-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Transkriptionsfaktor</subfield><subfield code="0">(DE-588)4303350-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Vaccinia-Virus</subfield><subfield code="0">(DE-588)4187306-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="o">urn:nbn:de:bvb:20-opus-85139</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-85139</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027058112&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-027058112</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV041617015 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T01:00:58Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-027058112 |
| oclc_num | 869895918 |
| open_access_boolean | 1 |
| owner | DE-384 DE-473 DE-BY-UBG DE-703 DE-1051 DE-824 DE-29 DE-12 DE-91 DE-BY-TUM DE-19 DE-BY-UBM DE-1049 DE-92 DE-739 DE-898 DE-BY-UBR DE-355 DE-BY-UBR DE-706 DE-20 DE-1102 |
| owner_facet | DE-384 DE-473 DE-BY-UBG DE-703 DE-1051 DE-824 DE-29 DE-12 DE-91 DE-BY-TUM DE-19 DE-BY-UBM DE-1049 DE-92 DE-739 DE-898 DE-BY-UBR DE-355 DE-BY-UBR DE-706 DE-20 DE-1102 |
| physical | 174 S. Ill., graph. Darst. |
| psigel | ebook |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| record_format | marc |
| spelling | Ehrig, Klaas 1983- Verfasser (DE-588)1047004798 aut Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy von Klaas Ehrig Effekte von Stammzell-Transkriptionsfaktor exprimierenden Vaccinia Viren in onkolytischer Virotherapie 2012 174 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Zsfassung in dt. und engl. Sprache. - Online erschienen: 2014 Würzburg, Univ., Diss., 2012 Vaccinia-Virus (DE-588)4187306-3 gnd rswk-swf Transkriptionsfaktor (DE-588)4303350-7 gnd rswk-swf Lungenkrebs (DE-588)4036668-6 gnd rswk-swf Darmkrebs (DE-588)4011068-0 gnd rswk-swf (DE-588)4113937-9 Hochschulschrift gnd-content Darmkrebs (DE-588)4011068-0 s Lungenkrebs (DE-588)4036668-6 s Transkriptionsfaktor (DE-588)4303350-7 s Vaccinia-Virus (DE-588)4187306-3 s DE-604 Erscheint auch als Online-Ausgabe urn:nbn:de:bvb:20-opus-85139 https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-85139 Resolving-System kostenfrei Volltext DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027058112&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Ehrig, Klaas 1983- Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy Vaccinia-Virus (DE-588)4187306-3 gnd Transkriptionsfaktor (DE-588)4303350-7 gnd Lungenkrebs (DE-588)4036668-6 gnd Darmkrebs (DE-588)4011068-0 gnd |
| subject_GND | (DE-588)4187306-3 (DE-588)4303350-7 (DE-588)4036668-6 (DE-588)4011068-0 (DE-588)4113937-9 |
| title | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy |
| title_alt | Effekte von Stammzell-Transkriptionsfaktor exprimierenden Vaccinia Viren in onkolytischer Virotherapie |
| title_auth | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy |
| title_exact_search | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy |
| title_full | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy von Klaas Ehrig |
| title_fullStr | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy von Klaas Ehrig |
| title_full_unstemmed | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy von Klaas Ehrig |
| title_short | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy |
| title_sort | effects of stem cell transcription factor expressing vaccinia viruses in oncolytic virotherapy |
| topic | Vaccinia-Virus (DE-588)4187306-3 gnd Transkriptionsfaktor (DE-588)4303350-7 gnd Lungenkrebs (DE-588)4036668-6 gnd Darmkrebs (DE-588)4011068-0 gnd |
| topic_facet | Vaccinia-Virus Transkriptionsfaktor Lungenkrebs Darmkrebs Hochschulschrift |
| url | https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-85139 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027058112&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT ehrigklaas effectsofstemcelltranscriptionfactorexpressingvacciniavirusesinoncolyticvirotherapy AT ehrigklaas effektevonstammzelltranskriptionsfaktorexprimierendenvacciniavireninonkolytischervirotherapie |